Matthew [Last Name Unknown]'s questions to Vir Biotechnology Inc (VIR) leadership • Q1 2025
Question
Matthew, on behalf of Alec Stranahan, asked for the rationale behind the four-part trial design for VIR-5525, which includes monotherapy and combination arms. He also questioned if VIR would still explore combinations if initial monotherapy data proves to be strong.
Answer
Marianne De Backer (Executive) explained that the combination with a checkpoint inhibitor is supported by scientific rationale, as T-cell engagers can upregulate PD-L1 and combinations have shown deeper, more durable responses in other TCEs. She confirmed the four-part design is intended to thoroughly explore both modalities, as the combination is expected to enhance efficacy regardless of monotherapy performance.